Recognizes an oncofetal antigen of 220kD, identified as a tumor-associated glycoprotein (TAG-72) with properties of a mucin. This monoclonal antibody defines the mucin-carried sialylated-Tn epitope. TAG-72 is usually expressed by adenocarcinomas, but is negative in mesotheliomas. Studies have reported that this antibody has 80% sensitivity and 93% specificity for pulmonary adenocarcinoma. Therefore, TAG-72 is a useful marker to distinguish between mesothelioma and adenocarcinoma. However, false positive reactions can occur so results must be interpreted with the utmost caution. This antibody may be useful in the differentiation of non-small cell carcinomas from small cell carcinomas of the lung. The combined use of anti-TAG-72 and anti-GCDFP-15 is valuable in the diagnosis of apocrine carcinoma.

Suitable for use in FLISA, Western Blot, Flow Cytometry (Not Tested), Immunoprecipitation, Immunofluorescence and Immunohistochemistry. Other applications not tested.

Flow Cytometry (Not Tested): 0.5-1ug/10e6 cells Western Blot: 0.5-1ug/ml Immunofluorescence: 1-2ug/ml Immunoprecipitation: 1-2ug/500ug protein lysate Immunohistochemistry (Frozen & Formalin fixed paraffin embedded): 0.5-1ug/ml/30min @ RT Optimal dilutions to be determined by the researcher.

Jurkat cells, Breast or lung carcinoma.

Store product at 4°C in the dark. DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: MaxLight™650 conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Note: Applications are based on unconjugated antibody.

Membrane-enriched fraction of a human breast carcinoma liver metastasis

Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with MaxLight™650.

Purified by Protein G affinity chromatography.

Recognizes human TAG-72. Species Crossreactivity: bovine, canine, hamster and rat. Stains the majority of human adenocarcinomas including colorectal, pancreatic, gastric, ovarian, endometrial, mammary and non-small cell lung cancer.